Research programme: cancer and inflammatory disease antibody-drug conjugates - Enzo Biochem/Innate Pharma
Latest Information Update: 28 Jul 2018
At a glance
- Originator Innate Pharma
- Developer Enzo Life Sciences; Innate Pharma
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in France
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA
- 28 Jul 2018 No recent reports of development identified for research development in Inflammation in France